Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder

Journal of Neuroendocrinology

Volumn 24, Issue 1, 2012, Pages 102-116

  Pinna, Graziano ^a   Rasmusson, Ann M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 reductase type I; Aggressive behaviour; Allopregnanolone; Anxiety; GABA A receptors; Post traumatic stress disorder; Selective brain steroidogenic stimulants; Social isolation

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR A; ALPRAZOLAM; ANTIDEPRESSANT AGENT; APOCYNIN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARRIER PROTEIN; CLOZAPINE; DIAZEPAM; EMAPUNIL; ETIFOXINE; FLUOXETINE; GANAXOLONE; GLUCOCORTICOID; LONG ACTING DRUG; NORFLUOXETINE; OLANZAPINE; PAROXETINE; PRASTERONE; PROGESTERONE; SELECTIVE BRAIN STEROIDOGENIC STIMULANT; SEROTONIN UPTAKE INHIBITOR; STEROID 5ALPHA REDUCTASE; TOPIRAMATE; TRANSLOCASE PROTEIN; UNCLASSIFIED DRUG;

AGGRESSION; ANXIETY DISORDER; BEHAVIOR DISORDER; CELL SURVIVAL; CEREBROSPINAL FLUID LEVEL; COMORBIDITY; DEPRESSION; DNA POLYMORPHISM; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; GABAERGIC TRANSMISSION; HORMONE BINDING; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MOUSE; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOCIAL ISOLATION; STEROIDOGENESIS; STRESS; UPREGULATION;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; FLUOXETINE; MICE; NEUROTRANSMITTER AGENTS; PREGNANOLONE; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; UP-REGULATION;

EID: 84055191662     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02234.x     Document Type: Review

References (188)

1. American Psychiatric Press. Diagnostic Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press, 2000.
2. Berton O, Nestler IJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
4. Costa E, Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Sci 1996; 17: 192-200.
5. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9: 248-312.
6. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. British association for psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-596.
7. A receptor subtype functions. Curr Opin Pharmacol 2006; 6: 18-23.
8. Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 2002; 5: 315-325.
9. Pinna G, Galici R, Schneider HH, Stephens DN, Turski L. Alprazolam dependence prevented by substituting with the beta-carboline abecarnil. Proc Natl Acad Sci USA 1997; 94: 2719-2723.
10. Viola J, Ditzler T, Batzer W, Harazin J, Adams D, Lettich L, Berigan T. Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990-1995. Mil Med 1997; 162: 616-619.
11. Davidson JR. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J Clin Psychiatry 2004; 65: 29-33.
12. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996; 57: 390-394.
13. Atack JR. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord 2003; 2: 213-232.
14. A receptor diversity emerges a unified vision of GABAergic inhibition. Annu Rev Pharmacol Toxicol 1998; 38: 321-350.
15. Puia G. Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor. Proc Natl Acad Sci USA 1992; 89: 3620-3624.
16. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology 2006; 186: 362-372.
17. Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, Krystal J, Guidotti A. Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. Biol Psychiatry 2006; 60: 704-713.
18. Nappi RE, Petraglia F, Luisi S, Polatti F, Farina C, Genazzani AR. Serum allopregnanolone in women with postpartum 'blues'. Obstet Gynecol 2001; 97: 77-80.
19. A receptor-modulationg neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry 2002; 159: 145-147.
20. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with presmenstrual syndrome. Obstet Gynecol 1997; 90: 709-714.
21. Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ. Proof-of concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsycopharmacology 2009; 34: 1885-1903.
22. Pearlstein T. Premenstrual dysphoric disorder: out of the appendix. Arch Womens Ment Health 2010; 13: 21-23.
23. Amin Z, Mason GF, Cavus I, Krystal JH, Rothman DL, Epperson CN. The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. J Psychopharmacol 2007; 21: 414-420.
24. Bäckström T, Andreen L, Birzniece V, Björn I, Johansson IM, Nordenstam-Haghjo M, Nyberg S, Sundström-Poromaa I, Wahlström G, Wang M, Zhu D. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003; 17: 325-342.
25. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000; 157: 924-930.
26. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95: 3239-3244.
27. Romeo E, Ströhle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998; 155: 910-913.
28. Serra M, Madau P, Chessa MF, Caddeo M, Sanna E, Trapani G, Franco M, Liso G, Purdy RH, Barbaccia ML, Biggio G. 2-Phenyl-imidazo[1, 2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. Br J Pharmacol 1999; 127: 177-187.
29. Rupprecht R, Rammes G, Eser D, Baghai TC et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009; 325: 490-493.
30. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971-988.
31. Schüle C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 2011; 191: 55-77.
32. A receptor activity. Psychoneuroendocrinology 2011; 36: 463-472.
33. Agis-Balboa RC, Guidotti A, Whitfield H, Pinna G. Allopregnanolone Biosynthesis is Downregulated in the Prefrontal Cortex/Brodmann's area 9 (BA9) of Depressed Patients. 2010 Neuroscience Meeting. San Diego, CA: Society for Neuroscience, 2010.
34. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology 2003; 165: 97-110.
35. Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA 1996; 93: 12599-12604.
36. Pinna G, Dong E, Matsumoto K, Costa E, Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proc Natl Acad Sci USA 2003; 100: 2035-2040.
37. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids. Proc Natl Acad Sci USA 2004; 101: 6222-6225.
38. Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol 2009; 9: 24-30.
39. Pinna G. In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav Pharmacol 2010; 21: 438-450.
40. Nin Schuler M, Martinez LA, Thomas R, Nelson M, Pinna G. Allopregnanolone and S-norfluoxetine decrease anxiety-like behavior in a mouse model of anxiety/depression. Trabajos del Instituto Cajal 2011; 83: 215-216.
41. Baulieu EE. Steroid hormones in the brain: several mechanisms. In: Fuxe K, Gustafson JA, Wettenberg L, eds. Steroid Hormone Regulation of the Brain. Elmsford, NY: Pergamon, 1981: 3-14.
42. Baulieu EE, Robel P, Schumacher M. Neurosteroids: beginning of the story. Int Rev Neurobiol 2001; 46: 1-32.
43. Cheney DL, Uzunov D, Costa E, Guidotti A. Gas chromatographic-mass fragmentographic quantitation of 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) and its precursors in blood and brain of adrenalectomized and castrated rats. J Neurosci 1995; 15: 4641-4650.
44. Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α-dihydroprogesterone in psychiatric disorders. Brain Res Rev 2001; 37: 110-115.
45. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001; 145: 669-679.
46. A receptors. Neuron 1990; 4: 759-765.
47. Puia G, Vicini S, Seeburg PH, Costa E. Influence of recombinant gamma-aminobutyric acid - a receptor subunit composition on the action of allosteric modulators of gammaaminobutyricacid-gated Cl-currents. Mol Pharmacol 1991; 39: 691-696.
48. A receptor function. Neuropharmacology 2003; 44: 49-55.
49. A receptor agonist muscimol. Neuropharmacology 2000; 39: 440-448.
50. A receptors. Prog Neurobiol 2003; 71: 67-80.
51. A receptors. Psychoneuroendocrinology 2009; 34(Suppl 1): S48-S58.
52. A receptor. Nat Rev Neurosci 2005; 6: 565-575.
53. A receptor. Mechanism of action and physiological significance. Prog Neurobiol 1992; 38: 379-395.
54. D'Aquila PS, Canu S, Sardella M, Spanu C, Serra G, Franconi F. Dopamine is involved in the antidepressant-like effect of allopregnanolone in the forced swimming test in female rats. Behav Pharmacol 2010; 21: 21-28.
55. A receptor gamma2 subunit mRNA after hippocampal administration of allopregnanolone in rats. J Psychopharmacol 2008; 22: 477-485.
56. A receptor. Behav Pharmacol 2009; 20: 614-622.
57. Kita A, Furukawa K. Involvement of neurosteroids in the anxiolytic-like effects of AC-5216 in mice. Pharmacol Biochem Behav 2008; 89: 171-178.
58. Lonsdale D, Burnham WM. The anticonvulsant effects of allopregnanolone against amygdalakindled seizures in female rats. Neurosci Lett 2007; 411: 147-151.
59. Mares P, Mikulecká A, Haugvicová R, Kasal A. Anticonvulsant action of allopregnanolone in immature rats. Epilepsy Res 2006; 70: 110-117.
60. Martin-Garcia E, Pallares M. The intrahippocampal administration of the neurosteroid allopregnanolone blocks the audiogenic seizures induced by nicotine. Brain Res 2005; 1062: 144-150.
61. Jain NS, Hirani K, Chopde CT. Reversal of caffeine-induced anxiety by neurosteroid 3-alpha-hydroxy-5-alpha-pregnane-20-one in rats. Neuropharmacology 2005; 48: 627-638.
62. A receptor subunit composition? Receptors Channels 1993; 1: 135-142.
63. Matsumoto K, Nomura H, Murakami Y, Taki K, Takahata H, Watanabe H. Long-term social isolation enhances picrotoxin seizure susceptibility in mice: up-regulatory role of endogenous brain allopregnanolone in GABAergic systems. Pharm Biochem Behav 2003; 75: 831-835.
64. A receptors through two discrete transmembrane sites. Nature 2006; 444: 486-489.
65. A receptors. Neuropharmacology 2002; 43: 651-661.
66. A receptor-chloride ion channel complex. Neuropsychopharmacology 1991; 4: 9-15.
67. Agis-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci USA 2006; 103: 14602-14607.
68. Agis-Balboa RC, Pinna G, Kadriu B, Costa E, Guidotti A. Downregulation of 5α-reductase type I mRNA expression in cortico-limbic glutamatergic circuits of mice socially isolated for four weeks. Proc Natl Acad Sci USA 2007; 104: 18736-18741.
69. Pinna G, Agis-Balboa R, Pibiri F, Nelson M, Guidotti A, Costa E. Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochem Res 2008; 33: 1990-2007.
70. A receptor. J Neurosc 2005; 25: 11605-11613.
71. Pinault D. The thalamic reticular nucleus: structure, function and concept. Brain Res Rev 2004; 46: 1-31.
72. Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3a-reduced neurosteroids to depression and antidepressant action. Psychopharmacology 2006; 186: 351-361.
73. Matsumoto K, Uzunova V, Pinna G, Taki K, Uzunov DP, Watanabe H, Mienvielle J-M, Guidotti A, Costa E. Permissive role of brain allopregnanolone content in the regulation of pentobarbital-induced righting reflex loss. Neuropharmacology 1999; 38: 955-963.
74. Serra M, Pisu MG, Littera M, Papi G, Sanna E, Tuveri F, Usala L, Purdy RH, Biggio G. Social isolation-induced decreases in both the abundance of neuroactive steroids and GABA(A) receptor function in rat brain. J Neurochem 2000; 75: 732-740.
75. Bortolato M, Devoto P, Roncada P, Frau R, Flore G, Saba P, Pistritto G, Soggiu A, Pisanu S, Zappala A, Ristaldi MS, Tattoli M, Cuomo V, Marrosu F, Barbaccia ML. Isolation rearing induced reduction of brain 5α-reductase expression: relevance to dopaminergic impairments. Neuropharmacology 2011; 60: 1301-1308.
76. A receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a nonserotonergic mechanism of action of SSRIs in mood and anxiety disorders. Stress 2007; 10: 3-12.
77. Dong E, Matsumoto K, Uzunova V, Sugaya I, Costa E, Guidotti A. Brain 5α-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc Natl Acad Sci USA 2001; 98: 2849-2854.
78. Pibiri F, Nelson M, Guidotti A, Costa E, Pinna G. Decreased allopregnanolone content during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proc Natl Acad Sci USA 2008; 105: 5567-5572.
79. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-409.
80. Nelson M, Pinna G. S-norfluoxetine infused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice. Neuropharmacology 2011; 60: 1154-1159.
81. Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol Biochem Behav 1998; 59: 221-232.
82. Frye CA, Rhodes ME. Infusions of 5alpha-pregnan-3alpha-ol-20-one (3alpha, 5alpha-THP) to the ventral tegmental area, but not the substantia nigra, enhance exploratory, antianxiety, social and sexual behaviours and concomitantly increase 3alpha, 5alpha-THP concentrations in the hippocampus, diencephalon and cortex of ovariectomised oestrogenprimed rats. J Neuroendocrinol 2006; 18: 960-975.
83. A receptor. Brain Res 1991; 561: 157-161.
84. Wieland S, Lan NC, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one. Brain Res 1991; 565: 263-268.
85. Deo GS, Dandekar MP, Upadhya MA, Kokare DM, Subhedar NK. Neuropeptide Y Y1 receptors in the central nucleus of amygdala mediate the anxiolytic-like effect of allopregnanolone in mice: behavioral and immunocytochemical evidences. Brain Res 2010; 1318: 77-86.
86. Engin E, Treit D. The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: the amygdala, medial prefrontal cortex, or hippocampus. Behav Pharmacol 2007; 18: 461-470.
87. Frye CA, Paris JJ, Rhodes ME. Increasing 3alpha, 5alpha-THP following inhibition of neurosteroid biosynthesis in the ventral tegmental area reinstates anti-anxiety, social, and sexual behavior of naturally receptive rats. Reproduction 2009; 137: 119-128.
88. A receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb Cortex 1995; 5: 550-560.
89. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, Opeskin K, Copolov DL. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 1999; 72: 1593-1599.
90. Lewis DA. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 2000; 31: 270-276.
91. A receptor gamma subunits in the prefrontal cortex of patients with schizophrenia and bipolar disorder. Neuroreport 2004; 15: 1809-1812.
92. A receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 2004; 44: 475-498.
93. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Möhler H. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999; 401: 796-800.
94. Pinna G, Agis-Balboa RC, Zhubi A, Matsumoto K, Grayson DR, Costa E, Guidotti A. Imidazenil and diazepam increase locomotor activity in mice exposed to protracted social isolation. Proc Natl Acad Sci USA 2006; 103: 4275-4280.
95. Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000; 131: 1251-1254.
96. Smith SS, Gong QH, Hsu FC, Markowitz RS, ffrench-Mullen JM, Li X. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998; 392: 926-930.
97. Valzelli L. The 'isolation syndrome' in mice. Psychopharmacologia 1973; 31: 305-320.
98. Matsumoto K, Cai B, Satoh T, Ohta H, Watanabe H. Desipramine enhances isolation induced aggressive behavior in mice. Pharmacol Biochem Behav 1991; 39: 167-170.
99. Valzelli L. Psychopharmacology of aggression: an overview. Int Pharmacopsychiatry 1981; 16: 39-48.
100. Fish EW, De Bold JF, Miczek KA. Aggressive behavior as a reinforcer in mice: activation by allopregnanolone. Psychopharmacology (Berl) 2002; 163: 459-466.
101. Engel SR, Grant KA. Neurosteroids and behavior. Int Rev Neurobiol 2001; 46: 321-348.
102. Dranovsky A, Picchini AM, Moadel T, Sisti AC, Yamada A, Kimura S, Leonardo ED, Hen R. Experience dictates stem cell fate in the adult hippocampus. Neuron 2011; 70: 908-923.
103. Kempermann G, Kronenberg G. Depressed new neurons - adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 2003; 54: 499-503.
104. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160.
105. Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 2006; 59: 1136-1143.
106. Kempermann G, Gage FH. Closer to neurogenesis in adult humans. Nat Med 1998; 4: 555-557.
107. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA 1999; 96: 13427-13431.
108. Leuner B, Mendolia-Loffredo S, Kozorovitskiy Y, Samburg D, Gould E, Shors TJ. Learning enhances the survival of new neurons beyond the time when the hippocampus is required for memory. J Neurosci 2004; 24: 7477-7481.
109. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, Drew M, Craig DA, Guiard BP, Guilloux JP, Artymyshyn RP, Gardier AM, Gerald C, Antonijevic IA, Leonardo ED, Hen R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009; 62: 479-493.
110. Wang JM, Liu L, Irwin RW, Chen S, Brinton RD. Regenerative potential of allopregnanolone. Brain Res Rev 2008; 57: 398-409.
111. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809.
112. Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, Arango V. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009; 34: 2376-2389.
113. Castro JE, Varea E, Márquez C, Cordero MI, Poirier G, Sandi C. Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat. PLoS ONE 2010; 5: e8618.
114. Wong EY, Herbert J. The corticoid environment: a determining factor for neural progenitors' survival in the adult hippocampus. Eur J Neurosci 2004; 20: 2491-2498.
115. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci 2002; 16: 445-453.
116. Pinnock SB, Lazic SE, Wong HT, Wong IH, Herbert J. Synergistic effects of dehydroepiandrosterone and fluoxetine on proliferation of progenitor cells in the dentate gyrus of the adult male rat. Neuroscience 2009; 158: 1644-1651.
117. Zhang Z, Yang R, Zhou R, Li L, Sokabe M, Chen L. Progesterone promotes the survival of newborn neurons in the dentate gyrus of adult male mice. Hippocampus 2010; 20: 402-412.
118. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 2005; 25: 4706-4718.
119. Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, Thompson RF, Brinton RD. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2010; 107: 6498-6503.
120. Brinton RD, Wang JM. Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 2006; 3: 11-17.
121. Keller EA, Zamparini A, Borodinsky LN, Gravielle MC, Fiszman ML. Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res 2004; 153: 13-17.
122. Papadopoulos V, Lecanu L. Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties. J Neuroendocrinol 2011; doi: [Epub ahead of print].
123. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011; 10: 209-219.
124. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
125. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008; 33: 56-72.
126. Quirk GJ, Milad MR. Neuroscience: editing out fear. Nature 2010; 463: 36-37.
127. Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 2007; 14: 268-276.
128. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
129. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-3913.
130. Sheline YI, Mittler BL, Mintun MA. The hippocampus and depression. Eur Psychiatry 2002; 17(Suppl 3): 300-305.
131. Schmahl C, Berne K, Krause A, Kleindienst N, Valerius G, Vermetten E, Bohus M. Hippocampus and amygdala volumes in patients with borderline personality disorder with or without posttraumatic stress disorder. J Psychiatry Neurosci 2009; 34: 289-295.
132. Acheson DT, Gresack JE, Risbrough VB. Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. Neuropharmacology 2011; 11 May 2011 [Epub ahead of Print].
133. Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003; 54: 693-702.
134. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-75.
135. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.
136. Nelson M, Pibiri F, Pinna G. Relationship between allopregnanolone (Allo) and reduced brain BDNF and reelin expression in a mouse model of posttraumatic stress disorders (PTSD), Society for Neuroscience 2010 Abstract, 666.22.
137. Tueting P, Pinna G. Behavior associated with an enriched environment and with social isolation in mice. Society for Neuroscience Abstract. Poster. Orlando, FL. 2-7 November 2002. 106.12.
138. Martinez LA, Pibiri F, Nelson M, Nin MS, Pinna G. Selective brain steroidogenic stimulant (SBSS)-induced neurosteroid upregulation facilitates fear extinction and reinstatement of fear memory by a BDNF-mediated mechanism in a mouse model of PTSD. Society for Neuroscience Abstract. Washington, DC. 12-16 November 2011.
139. Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 2007; 6: 127-140.
140. Sanacora G. Cortical Inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire? Biol Psychiatry 2010; 67: 397-398.
141. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry 2000; 157: 1120-1126.
142. Kugaya A, Verhoeff NP, Seibyl JP, Innis RB. Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder. Biol Psychiatry 2004; 56: 95-100.
143. Fujita M, Southwick SM, Denucci CC, Zoghbi SS, Dillon MS, Baldwin RM, Bozkurt A, Kugaya A, Verhoeff NP, Seibyl JP, Innis RB. Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder. Biol Psychiatry 2004; 15: 95-100.
144. Vaiva G, Thomas P, Ducrocq F, Fontaine M, Boss V, Devos P, Rascle C, Cottencin O, Brunet A, Laffargue P, Goudemand M. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry 2004; 55: 250-254.
145. Feusner J, Ritchie T, Lawford B, Young RM, Kann B, Noble EP. GABA(A) receptor beta 3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population. Psychiatry Res 2001; 104: 109-117.
146. A-antagonistic neurosteroids in patients with combat-related posttraumatic stress disorder. Psychol Med 2000; 30: 1227-1231.
147. Sondergaard HP, Hansson L-O, Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother Psychosom 2002; 71: 298-303.
148. Rasmusson AM, Vasek J, Lipschitz DS, Vojvoda D, Mustone ME, Shi Q, Gudmundsen G, Morgan CA, Wolfe J, Charney DS. An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. Neuropsychopharm 2004; 29: 1546-1557.
149. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes C, Farfel GM. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA 2000; 283: 1837-1844.
150. Davidson JRT, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58: 485-492.
151. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetinetreatment for PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158: 1982-1988.
152. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexibledosage study. J Clin Psychiatry 2001; 62: 860-868.
153. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, doubleblind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007; 68: 711-720.
154. A receptors mediate tonic inhibition in hippocampal dentate granule cells. Molecular Pharm 2006; 69: 564-575.
155. Ressler KJ, Paschall G, Zhou XL, Davis M. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci 2002; 22: 7892-7902.
156. Myers KM, Davis M. Mechanisms of fear extinction. Molecular Psychiatry 2007; 12: 120-150.
157. Barbaccia ML, Serra M, Purdy RH, Biggio G. Stress and neuroactive steroids. Int Rev Neurobiol 2001; 46: 243-272.
158. Breslau N, Chase GA, Anthony JC. The uniqueness of the DSM definition of post-traumatic stress disorder: implications for research. Psychol Med 2002; 32: 573-576.
159. Zhao H, Mayhan WG, Arrick DM, Xiong W, Sun H. Alcohol-induced exacerbation of ischemic brain injury: role of NAD(P)H oxidase. Alcoholism: Clin Exp Res 2010; 34: 1948-1955.
160. Cagetti E, Pinna G, Guidotti A, Baicy K, Olsen RW. Chronic intermittent ethanol (CIE) administration in rats decreases levels of neurosteroids in hippocampus, accompanied by altered behavioral responses to neurosteroids and memory function. Neuropharmacology 2004; 46: 570-579.
161. Penning TM, Jin Y, Steckelbroeck S, Lanisnik Rizner T, Lewis M. Structure-function of human 3-hydroxysteroid dehydrogenases genes and proteins. Mol Cell Endocrin 2004; 215: 63-72.
162. Penning TM. 3α-Hydroxysteroid dehydrogenase: three dimensional structure and gene regulation. J. Endocrinology 1996; 150: 5175-5187.
163. Tomkins GM. Enzymatic mechanisms of hormone metabolism. I. Oxidation-reduction of the steroid nucleus. Recent Prog Horm Res 1956; 12: 125-133.
164. Hou YT, Lin HK, Penning TM. Dexamethasone regulation of the rat 3-hydroxysteroid/dihydrodiol dihydrogenase (3α-HSD/DD) gene. Mol Pharmacol 1998; 53: 459-466.
165. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999; 96: 13512-13517.
166. Trauger JW, Jiang A, Stearns BA, LoGrasso PV. Kinetics of allopregnanolone formation catalyzed by human 3 alpha hydroxysteroid dehydrogenase Type III (AKR1C2). Biochemistry 2002; 41: 13451-13459.
167. Chung ES, Chung YC, Boka E, Baik HH, Park ES, Parke J-Y, Yoon SH, Jin BK. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res 2010; 1363: 143-150.
168. Gulinello M, Gong QH, Smith SS. Progesterone withdrawal increases the anxiolytic actions of gaboxadol: role of alpha4betadelta GABA(A) receptors. Neuroreport 2003; 14: 43-46.
169. Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004; 45: 864-867.
170. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004; 4: 24.
171. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Int Med 2005; 165: 1600-1605.
172. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharm 2003; 28: 1-13.
173. Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR. Longterm low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003; 80: 1495-1501.
174. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005; 62: 154-162.
175. Hamner MB. Clozapine treatment for a veteran with psychosis and PTSD. Am J Psychiatry 1996; 153: 841.
176. Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC, Teten AL, Worchel J, Young KA. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001; 16: 331-337.
177. Barbaccia ML. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Crit Rev Neurobiol 2004; 16: 67-74.
178. Suris A, North C, Adinoff B, Powell CM, Greene R. Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Ann Clin Psychiatry 2010; 22: 274-279.
179. Brandes RP. A radical adventure: the quest for specific functions and inhibitors of vascular NAPDH oxidases. Circ Res 2003; 92: 583-585.
180. Rasmusson AM, Schnurr P, Zukowska Z, Scioli E, Forman DE. Adaptation to extreme stress: PTSD, NPY, and metabolic syndrome. Exp Biol Med 2010; 235: 1150-1156.
181. Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 2000; 21: 1-56.
182. Reddy DS, Kulkarni SK. Role of GABA-A and mitochondrial diazepam binding inhibitor receptors in the anti-stress activity of neurosteroids in mice. Psychopharmacology 1996; 128: 280-292.
183. Romeo E, Auta J, Kozikowski AP, Ma D, Papadopoulos V, Puia G, Costa E, Guidotti A. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J Pharmacol Exp Ther 1992; 262: 971-978.
184. Korneyev A, Pan BS, Polo A, Romeo E, Guidotti A, Costa E. Stimulation of brain pregnenolone synthesis by mitochondrial diazepam binding inhibitor receptor ligands in vivo. J Neurochem 1993; 61: 1515-1524.
185. Kita A, Kohayakawa H, Kinoshita T, Ochi Y, Nakamichi K, Kurumiya S, Furukawa K, Oka M. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br J Pharmacol 2004; 142: 1059-1072.
186. Girard C, Liu S, Cadepond F, Adams D, Lacroix C, Verleye M, Gillardin JM, Baulieu EE, Schumacher M, Schweizer-Groyer G. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc Natl Acad Sci USA 2008; 105: 20505-20510.
187. Peters J, Dieppa-Perea LM, Melendez LM, Quirk GJ. Induction of fear extinction with hippocampal-infralimbic BDNF. Science 2010; 328: 1288-1290.
188. A Receptor plasticity. Psychoneuroendocrinology 2009; 34(Suppl 1): S84-S90.